跳至主要内容
临床试验/CTIS2022-502385-24-00
CTIS2022-502385-24-00进行中(未招募)1 期

22292

Bayer AG0 个研究点目标入组 60 人开始时间: 2023年1月9日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Bayer AG
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)
性别
Male

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Bayer AG

相似试验

招募中
1 期
A study to learn about the taste of Vericiguat given in liquid form in healthy male participants aged 18 to 45 years
CTIS2023-508447-52-00Bayer AG20
进行中(未招募)
1 期
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.MedDRA version: 20.1Level: LLTClassification code: 10054109Term: Non-proliferative diabetic retinopathy Class: 10015919MedDRA version: 23.1Level: PTClassification code: 10064848Term: Chronic kidney disease Class: 100000004857Chronic kidney disease
CTIS2024-510856-11-00Bayer AG15
招募中
1 期
A first in human single dose escalation study to investigate the safety, tolerability, pharmacokinetics, and pharmcodynamics of BAY 3389934 compared with placebo.Sepsis associated disseminated intravascular coagulationMedDRA version: 22.0Level: PTClassification code: 10013442Term: Disseminated intravascular coagulation Class: 100000004851MedDRA version: 20.0Level: PTClassification code: 10040047Term: Sepsis Class: 100000004862
CTIS2022-502866-25-00Bayer AG86
进行中(未招募)
1 期
First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expressionMedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104
CTIS2023-507486-26-00Bayer Consumer Care AG135
进行中(未招募)
1 期
A study to learn about how much elinzanetant gets absorbed in the blood and how safe it is in healthy participants when taken as different types of formulationsVasomotor symptoms as a sex hormone-dependent disorder in women and menMedDRA version: 20.0Level: LLTClassification code: 10067819Term: Andropausal symptoms Class: 10014698MedDRA version: 21.0Level: LLTClassification code: 10020407Term: Hot flashes Class: 10047065MedDRA version: 21.1Level: PTClassification code: 10027304Term: Menopausal symptoms Class: 100000004872
CTIS2023-503968-16-00Bayer Consumer Care AG16